Bristol Myers Squibb

Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff
BioSpace
layoffs
Rain Oncology
Takeda
PTC Therapeutics
Affimed
Urovant Sciences
Roche
Novavax
Gossamer Bio
Bristol Myers Squibb
ADC Therapeutics
Flag link:
Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
ASCO: BMS pitches Breyanzi as the first CAR-T for CLL. But will a single-arm trial persuade the FDA?
Fierce Pharma
ASCO 2023
Bristol Myers Squibb
Breyanzi
CAR-T
CLL
SLL
clinical trials
Flag link:
Bristol Myers data make case for earlier use of bone marrow disease drug
Bristol Myers data make case for earlier use of bone marrow disease drug
BioPharma Dive
Bristol Myers Squibb
Reblozyl
Epogen
myelodysplastic syndromes
clinical trials
Flag link:
Bristol Myers Squibb eyes phase 3 after pulmonary fibrosis drug reduces lung function decline
Bristol Myers Squibb eyes phase 3 after pulmonary fibrosis drug reduces lung function decline
Fierce Biotech
Bristol Myers Squibb
clinical trials
BMS-986278
idiopathic pulmonary fibrosis
Flag link:
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs
Medical Marketing and Media
layoffs
Bristol Myers Squibb
Roche
Takeda
Gossamer Bio
Novavax
Flag link:
The waxing and waning of the speedy approval
The waxing and waning of the speedy approval
EP Vantage
FDA
drug approvals
accelerated approvals
AbbVie
AstraZeneca
Bayer
Bristol Myers Squibb
JNJ
Merck
Merck KGaA
Novartis
Pfizer
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
BMS Cuts Jobs in New Jersey, Cites ‘Constantly Evolving’ Business Model
BMS Cuts Jobs in New Jersey, Cites ‘Constantly Evolving’ Business Model
BioSpace
Bristol Myers Squibb
layoffs
R&D
New Jersey
Flag link:
Biopharma Bets Big on Antibody-Drug Conjugates
Biopharma Bets Big on Antibody-Drug Conjugates
BioSpace
antibody-drug conjugate
Merck
Seagen
M&A
AstraZeneca
BioNTech
Bristol Myers Squibb
Flag link:
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again
Fierce Pharma
Bristol Myers Squibb
Opdivo
patents
legal
AstraZeneca
Flag link:
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
AbbVie, Bristol Myers vied for Prometheus before Merck bought it
Crain's Chicago Business
Merck
Prometheus Biosciences
M&A
AbbVie
Bristol Myers Squibb
Flag link:
FDA Accepts sBLA of BMS' Reblozyl
FDA Accepts sBLA of BMS' Reblozyl
Targeted Oncology
Bristol Myers Squibb
Reblozyl
FDA
MDS
anemia
Flag link:
Bristol Myers CEO Caforio steps down
Bristol Myers CEO Caforio steps down
Yahoo/Reuters
Bristol Myers Squibb
Pharma CEOs
Giovanni Caforio
Christopher Boerner
Flag link:
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
AbbVie
Amgen
Bristol Myers Squibb
Eli Lilly
Gilead Sceinces
JNJ
Merck
Pfizer
Regeneron
patents
activists
Flag link:
Bristol Myers boosts cell therapy production with Novartis plant
Bristol Myers boosts cell therapy production with Novartis plant
BioPharma Dive
Bristol Myers Squibb
cell therapy
Novartis
drug manufacturing
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Big pharma’s biggest spenders revealed: 2022 edition
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
Flag link:
BMS signs ADC development deal with Munich-based biotech worth more than $1B
BMS signs ADC development deal with Munich-based biotech worth more than $1B
Medical Marketing and Media
Bristol Myers Squibb
Tubulius
cancer
solid tumors
antibody-drug conjugate
Flag link:
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Flag link:

Pages